References
1. Sethi, S., New ’Antigens’ in Membranous Nephropathy. J Am Soc
Nephrol, 2021. 32 (2): p. 268-278.
2. JONES, D., Nephrotic glomerulonephritis. The American journal
of pathology, 1957. 33 (2): p. 313-29.
3. Beck, L.H., Jr., et al., M-type phospholipase A2 receptor as
target antigen in idiopathic membranous nephropathy. N Engl J Med,
2009. 361 (1): p. 11-21.
4. Tomas, N.M., et al., Thrombospondin type-1 domain-containing 7A
in idiopathic membranous nephropathy. N Engl J Med, 2014.371 (24): p. 2277-2287.
5. Ronco, P. and H. Debiec, Membranous nephropathy: current
understanding of various causes in light of new target antigens. Curr
Opin Nephrol Hypertens, 2021.
6. Schieppati, A., et al., Nonimmunosuppressive therapy of
membranous nephropathy. Seminars in Nephrology, 2003. 23 (4):
p. 333-339.
7. Gansevoort, R.T., et al., Antiproteinuric drugs in patients
with idiopathic membranous glomerulopathy. Nephrol Dial Transplant,
1992. 7 Suppl 1 : p. 91-6.
8. Kosmadakis, G., et al., Comparison of the influence of
angiotensin-converting enzyme inhibitor lisinopril and angiotensin II
receptor antagonist losartan in patients with idiopathic membranous
nephropathy and nephrotic syndrome. Scand J Urol Nephrol, 2010.44 (4): p. 251-6.
9. Mizuno, T., et al., KDIGO (Kidney Disease: Improving Global
Outcomes) criteria could be a useful outcome predictor of
cisplatin-induced acute kidney injury. Oncology, 2012. 82 (6):
p. 354-9.
10. Tran, T.H., et al., Overview of current and alternative
therapies for idiopathic membranous nephropathy. Pharmacotherapy, 2015.35 (4): p. 396-411.
11. De Vriese, A.S., et al., A Proposal for a Serology-Based
Approach to Membranous Nephropathy. Journal of the American Society of
Nephrology, 2017. 28 (2): p. 421-430.
12. Cattran, D.C. and P.E. Brenchley, Membranous nephropathy:
integrating basic science into improved clinical management. Kidney
Int, 2017. 91 (3): p. 566-574.
13. Vacchi, C., et al., Efficacy and safety of rituximab in the
treatment of connective tissue disease-related interstitial lung
disease. Drugs Context, 2021. 10 .
14. Semac, I., et al., Anti-CD20 therapeutic antibody rituximab
modifies the functional organization of rafts/microdomains of B lymphoma
cells. Cancer Res, 2003. 63 (2): p. 534-40.
15. Bonavida, B., Rituximab-induced inhibition of antiapoptotic
cell survival pathways: implications in chemo/immunoresistance,
rituximab unresponsiveness, prognostic and novel therapeutic
interventions. Oncogene, 2007. 26 (25): p. 3629-36.
16. Manches, O., et al., In vitro mechanisms of action of
rituximab on primary non-Hodgkin lymphomas. Blood, 2003.101 (3): p. 949-54.
17. Wang, S.Y., et al., NK-cell activation and antibody-dependent
cellular cytotoxicity induced by rituximab-coated target cells is
inhibited by the C3b component of complement. Blood, 2008.111 (3): p. 1456-63.
18. Roccatello, D., et al., New insights into immune mechanisms
underlying response to Rituximab in patients with membranous
nephropathy: A prospective study and a review of the literature.Autoimmun Rev, 2016. 15 (6): p. 529-38.
19. Ponticelli, C., et al., A 10-year follow-up of a randomized
study with methylprednisolone and chlorambucil in membranous
nephropathy. Kidney Int, 1995. 48 (5): p. 1600-4.
20. Ruggenenti, P., et al., Rituximab in idiopathic membranous
nephropathy. J Am Soc Nephrol, 2012. 23 (8): p. 1416-25.
21. Cravedi, P., et al., Efficacy and safety of rituximab
second-line therapy for membranous nephropathy: a prospective,
matched-cohort study. Am J Nephrol, 2011. 33 (5): p. 461-8.
22. Roccatello, D., R. Fenoglio, and S. Sciascia, Efficacy of low
or standard dose rituximab as compared to Ponticelli’s regimen in
membranous nephropathy. Nephrology Dialysis Transplantation, 2019.34 : p. a123.
23. Ruggenenti, P., F.C. Fervenza, and G. Remuzzi, Treatment of
membranous nephropathy: time for a paradigm shift. Nat Rev Nephrol,
2017. 13 (9): p. 563-579.
24. KDIGO 2020 Clinical Practice Guideline for Diabetes Management
in Chronic Kidney Disease. Kidney Int, 2020. 98 (4s): p.
S1-s115.
25. Dahan, K., et al., Rituximab for Severe Membranous
Nephropathy: A 6-Month Trial with Extended Follow-Up. J Am Soc Nephrol,
2017. 28 (1): p. 348-358.
26. Seitz-Polski, B., et al., Phospholipase A2 Receptor 1 Epitope
Spreading at Baseline Predicts Reduced Likelihood of Remission of
Membranous Nephropathy. J Am Soc Nephrol, 2018. 29 (2): p.
401-408.
27. Rosenzwajg, M., et al., B- and T-cell subpopulations in
patients with severe idiopathic membranous nephropathy may predict an
early response to rituximab. Kidney Int, 2017. 92 (1): p.
227-237.
28. van den Brand, J., et al., Safety of Rituximab Compared with
Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. J
Am Soc Nephrol, 2017. 28 (9): p. 2729-2737.
29. Fervenza, F.C., et al., Rituximab or Cyclosporine in the
Treatment of Membranous Nephropathy. N Engl J Med, 2019.381 (1): p. 36-46.
30. Fenoglio, R., et al., Efficacy of low or standard
rituximab-based protocols and comparison to Ponticelli’s regimen in
membranous nephropathy. J Nephrol, 2020.
31. Cravedi, P., et al., Titrating rituximab to circulating B
cells to optimize lymphocytolytic therapy in idiopathic membranous
nephropathy. Clinical journal of the American Society of Nephrology :
CJASN, 2007. 2 (5): p. 932-937.
32. Sugiura, H., et al., Effect of single-dose rituximab on
primary glomerular diseases. Nephron Clin Pract, 2011. 117 (2):
p. c98-105.
33. Ramachandran, R., et al., CD19 Targeted Low-Dose Rituximab Is
Effective in the Management of Refractory Phospholipase A2 Receptor
Antibody-Associated Membranous Nephropathy. Kidney Int Rep, 2017.2 (1): p. 89-90.
34. Moroni, G., et al., Low-dose rituximab is poorly effective in
patients with primary membranous nephropathy. Nephrol Dial Transplant,
2017. 32 (10): p. 1691-1696.
35. Remuzzi, G., et al., Rituximab for idiopathic membranous
nephropathy. Lancet, 2002. 360 (9337): p. 923-4.
36. Ruggenenti, P., et al., Rituximab for idiopathic membranous
nephropathy (IMN): Renal biopsy findings predict response to treatment.Journal of the American Society of Nephrology, 2003. 14 : p.
528A-528A.
37. Ruggenenti, P., et al., Rituximab for idiopathic membranous
nephropathy: who can benefit? Clin J Am Soc Nephrol, 2006.1 (4): p. 738-48.
38. Fervenza, F.C., et al., Response to ’rituximab in membranous
nephropathy’. Kidney International, 2008. 74 (3): p. 392-392.
39. Fervenza, F.C., et al., Rituximab treatment of idiopathic
membranous nephropathy. Kidney International, 2008. 73 (1): p.
117-125.
40. Fervenza, F.C., et al., Rituximab Therapy in Idiopathic
Membranous Nephropathy: A 2-Year Study. Clinical Journal of the
American Society of Nephrology, 2010. 5 (12): p. 2188-2198.
41. Busch, M., et al., Rituximab for the second- and third-line
therapy of idiopathic membranous nephropathy: a prospective single
center study using a new treatment strategy. Clin Nephrol, 2013.80 (2): p. 105-13.
42. Bagchi, S., et al., Low-dose Rituximab therapy in resistant
idiopathic membranous nephropathy: single-center experience. Clin
Kidney J, 2018. 11 (3): p. 337-341.
43. Huang, L., et al., Rituximab for the management of idiopathic
membranous nephropathy: a meta-analysis. Int Urol Nephrol, 2020.
44. Zhang, J., et al., Efficacy and safety of rituximab therapy
for membranous nephropathy: a meta-analysis. Eur Rev Med Pharmacol Sci,
2018. 22 (22): p. 8021-8029.
45. Lu, W., et al., Efficacy and safety of rituximab in the
treatment of membranous nephropathy: A systematic review and
meta-analysis. Medicine (Baltimore), 2020. 99 (16): p. e19804.
46. Dahan, K., et al., Rituximab for Severe Membranous
Nephropathy: A 6-Month Trial with Extended Follow-Up. Journal of the
American Society of Nephrology, 2017. 28 (1): p. 348-358.
47. Fervenza, F.C., et al., A Multicenter Randomized Controlled
Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic
Membranous Nephropathy (MENTOR). Nephron, 2015. 130 (3): p.
159-68.
48. Ruggenenti, P., P. Cravedi, and G. Remuzzi, Rituximab for
membranous nephropathy and immune disease: less might be enough. Nat
Clin Pract Nephrol, 2009. 5 (2): p. 76-7.
49. Remuzzi, G., et al., Rituximab for idiopathic membranous
nephropathy. Lancet, 2002. 360 (9337): p. 923-924.
50. Seitz-Polski, B., et al., High-Dose Rituximab and Early
Remission in PLA2R1-Related Membranous Nephropathy. Clin J Am Soc
Nephrol, 2019. 14 (8): p. 1173-1182.
Table 1 Characteristics of the studies on the comparison of RTX
and traditional therapies for remission included in the analysis.